Last updated on February 2018

A Study Comparing the Efficacy and Safety Between I-CHOP and R-CHOP in Untreated CD20-Positive Diffuse Large B-cell Lymphoma Patients

Are you eligible to participate in this study?

You may be eligible for this study if you meet the following criteria:

  • Conditions: Diffuse Large B-Cell Lymphoma
  • Age: Between 18 - 70 Years
  • Gender: Male or Female

Inclusion Criteria:

  • Untreated CD20-positive DLBCL confirmed by histopathology or cytology.
  • 18 years to 70 years; Male or female patients.
  • International Prognostic Index (IPI) score of 0 to 2.
  • Signed an informed consent.
  • At least one measurable lesions: for nodal tumor mass, more than 1.5 cm in the long axis and more than 1.0 cm in the short axis; for extranodal tumor mass, more than 1.0 cm in the long axis.
  • Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 2.
  • More than 6 months life expectancy.

Exclusion Criteria:

  • Participation in another interventional clinical trial in the past 3 months.
  • Known allergic reactions against monoclonal antibody or rituximab.
  • Contraindication to any component of CHOP regimen.
  • Previous treatment for DLBCL, including chemotherapy, immunotherapy, partial radiotherapy for lymphoma, or surgical treatment (excluding tumor mass biopsies and surgical resection for non-lymphoma lesions), or prior use of any monoclonal antibody within 3 month.
  • History of cytotoxic drugs treatment or anti-CD20 monoclonal antibody treatment for other disease (e.g., rheumatoid arthritis).
  • Primary central nervous system (CNS) lymphoma, secondary CNS involvement, primary testicular lymphoma.

Recruitment Status: Open

Brief Description Eligibility Contact Research Team

Receive Emails About New Clinical Trials!

Sign up for our FREE service to receive email notifications when clinical trials are posted in the medical category of interest to you.